Active Ingredient History

NOW
  • Now
Netarsudil ophthalmic solution (Rhopressa) is a Rho kinase inhibitor for the treatment of open-angle glaucoma or ocular hypertension. As of December 18, 2017 the FDA approved Aerie Pharmaceutical's Rhopressa (netarsudil ophthalmic solution) 0.02% for the indication of reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Acting as both a rho kinase inhibitor and a norepinephrine transport inhibitor, Netarsudil is a novel glaucoma medication in that it specifically targets the conventional trabecular pathway of aqueous humour outflow to act as an inhibitor to the rho kinase and norepinephrine transporters found there as opposed to affecting protaglandin F2-alpha analog like mechanisms in the unconventional uveoscleral pathway that many other glaucoma medications demonstrate.   NCATS

  • SMILES: Cc1ccc(C(=O)OCC2=CCC(C=C2)[C@@H](CN)C(=O)Nc3ccc4cnccc4c3)c(C)c1.CS(=O)(=O)O.CS(=O)(=O)O
  • InChIKey: RIYFCYMNMHPKGL-DCHFXQLBSA-N
  • Mol. Mass: 647.77
  • ALogP: 4.72
  • ChEMBL Molecules:
More Chemistry

Drug Pricing (per unit)

United States

$61.7933 - $108.7392
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Combination drugs

ar-13324 | netarsudil | netarsudil dimesylate

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue